Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy
NCT ID: NCT01645059
Last Updated: 2014-01-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
129 participants
OBSERVATIONAL
2011-07-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years
NCT01433926
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
NCT04578106
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer
NCT04857619
HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia
NCT05905939
Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
NCT04807595
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with disseminated breast cancer histologically or cytological confirmed, who begins with Her 2+ metastatic breast cancer or develops a metastasis after or during the adjuvant therapy
* Patients treated in first line treatment in metastatic disease.
* Patients who have positive Her 2 receptor test
* Patients who have given their written informed consent
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asociación Cacereña para la Investigación y el Desarrollo en Oncología Médica
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mª Helena López Ceballos, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital San Pedro Alcántara
Santiago González Santiago, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital San Pedro Alcántara
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Denia
Denia, Alicante, Spain
Hospital General de Elda
Elda, Alicante, Spain
Hospital de Torrecárdenas
Almería, Almería, Spain
Hospital Infanta Cristina de Badajoz
Badajoz, Badajoz, Spain
Hospital don Benito
Don Benito, Badajoz, Spain
Hospital de Llerena
Llerena, Badajoz, Spain
Hospital de Mérida
Mérida, Badajoz, Spain
Hospital Son Llàtzer
Palma de Mallorca, Balearic Islands, Spain
ICO Badalona
Badalona, Barcelona, Spain
Clínica Corachan
Barcelona, Barcelona, Spain
Hospital General de l'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Complejo Hospitalario Ciudad Real
Ciudad Real, Ciudad Real, Spain
Hospital San Pedro Alcántara
Cáceres, Cáceres, Spain
Hospital Virgen del Puerto
Plasencia, Cáceres, Spain
Hospital de Jerez
Jerez de la Frontera, Cádiz, Spain
Hospital de León
León, León, Spain
Hospital Universitario Arnau de Vilanova
Lleida, Lleida, Spain
Hospital Lucus Augusti
Lugo, Lugo, Spain
Hospital de Getafe
Getafe, Madrid, Spain
Hospital Severo Ochoa
Leganés, Madrid, Spain
Hospital La Princesa
Madrid, Madrid, Spain
Hospital de Móstoles
Móstoles, Madrid, Spain
Hospital Quirón
Pozuelo de Alarcón, Madrid, Spain
Hospital Morales Messeguer
Murcia, Murcia, Spain
Hospital Reina Sofía de Tudela
Tudela, Navarre, Spain
Hospital do Meixoeiro
Vigo, Pontevedra, Spain
Hospital de Cabueñes
Gijón, Principality of Asturias, Spain
Hospital General de Segovia
Segovia, Segovia, Spain
Hospital Virgen de la Macarena
Seville, Sevilla, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Hospital Universitario de la Candelaria
Santa Cruz de Tenerife, Tenerife, Spain
Hospital de Alcañiz
Alcañiz, Teruel, Spain
Hospital General Universitario de Valencia
Valencia, Valencia, Spain
Hospital Dr.Peset
Valencia, Valencia, Spain
Hospital Clínico de Valladolid
Valladolid, Valladolid, Spain
Hospital Universitario Rio Hortega
Valladolid, Valladolid, Spain
Hospital de Galdakao
Galdakao, Vizcaya, Spain
Hospital de Zamora
Zamora, Zamora, Spain
Hospital de Txagorritxu
Vitoria-Gasteiz, Álava, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACI-CMM-2010-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.